Clear Street on Palvella Therapeutics (PVLA): 'We view this patent as incrementally positive'

March 16, 2026 1:19 PM

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $220.00 price target on Palvella Therapeutics (NASDAQ: PVLA).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found